文献速递糖尿病

卡格列净对不同基线HbA1c、病程及治疗强度患者心血管与肾脏结局的影响:CANVAS项目结果

Effects of canagliflozin compared with placebo on major adverse cardiovascular and kidney events in patient groups with different baseline levels of HbA1c, disease duration and treatment intensity: results from the CANVAS Program.
PubMed 文献 · Diabetologia · 2021-08-26

CANVAS项目的事后分析按基线降糖治疗强度、糖尿病病程和HbA1c分层,评估卡格列净对比安慰剂对主要不良心血管事件(MACE)及肾脏复合结局的影响。卡格列净降低MACE(HR 0.86 [95%CI 0.75, 0.97])和肾脏复合结局(HR 0.60 [95%CI 0.47, 0.77]),各亚组间无异质性证据。

要点

  • 卡格列净降低MACE(HR 0.86 [95%CI 0.75, 0.97]),各治疗强度、病程及HbA1c亚组间无异质性。
  • 接受胰岛素治疗者MACE风险比HR 0.85(95%CI 0.72, 1.00),与其他参与者无差异证据。
  • 肾脏复合结局HR 0.60(95%CI 0.47, 0.77),各亚组异质性检验p>0.37。

核心结论

  • 在高心血管风险的2型糖尿病患者中,无证据表明卡格列净的心血管和肾脏保护作用因基线治疗强度、糖尿病病程或HbA1c不同而存在差异。

研究设计与样本

  • CANVAS项目的事后分析,按基线降糖治疗(0或1种、2或3种以上非胰岛素降糖药、胰岛素为基础治疗)、糖尿病病程(<10、10至16、>16年)及HbA1c分层。
  • 研究开始时5095例(50%)参与者接受胰岛素治疗,2100例(21%)HbA1c>74.9 mmol/mol(9.0%),糖尿病病程中位12.6年(四分位区间8.0-18年)。
  • 采用Cox回归分析,并通过拟合交互项比较各亚组HR的一致性(显著性p值<0.05)。

主要发现

  • 卡格列净降低MACE(HR 0.86 [95%CI 0.75, 0.97]),按降糖治疗数量、糖尿病病程或基线HbA1c定义的亚组间获益无差异证据(异质性p均>0.17)。
  • 接受胰岛素治疗的参与者中卡格列净降低MACE(HR 0.85 [95%CI 0.72, 1.00]),无证据显示其获益与其他参与者不同。
  • 其他心血管结局及肾脏复合结局(eGFR持续下降40%、终末期肾病或肾病死亡)结果相似,肾脏复合结局HR 0.60(95%CI 0.47, 0.77),异质性p均>0.37。

临床怎么用

  • 对高心血管风险的2型糖尿病患者,无论基线降糖治疗强度、糖尿病病程长短或HbA1c水平如何,均可考虑使用卡格列净以获得心血管和肾脏获益。

局限性

  • 本文为CANVAS项目的事后分析,亚组分析结果需谨慎解读。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS/HYPOTHESIS: Type 2 diabetes mellitus can manifest over a broad clinical range, although there is no clear consensus on the categorisation of disease complexity. We assessed the effects of canagliflozin, compared with placebo, on cardiovascular and kidney outcomes in the CANagliflozin cardioVascular Assessment Study (CANVAS) Program over a range of type 2 diabetes mellitus complexity, defined separately by baseline intensity of treatment, duration of diabetes and glycaemic control. METHODS: We performed a post hoc analysis of the effects of canagliflozin on major adverse cardiovascular events (MACE) according to baseline glucose-lowering treatments (0 or 1, 2 or 3+ non-insulin glucose-lowering treatments, or insulin-based treatment), duration of diabetes (<10, 10 to 16, >16 years) and HbA1c (≤53.0 mmol/mol [<7.0%], >53.0 to 58.5 mmol/mol [>7.0% to 7.5%], >58.5 to 63.9 mmol/mol [>7.5 to 8.0%], >63.9 to 69.4 mmol/mol [8.0% to 8.5%], >69.4 to 74.9 mmol/mol [>8.5 to 9.0%] or >74.9 mmol/mol [>9.0%]). We analysed additional secondary endpoints for cardiovascular and kidney outcomes, including a combined kidney outcome of sustained 40% decline in eGFR, end-stage kidney disease or death due to kidney disease. We used Cox regression analyses and compared the constancy of HRs across subgroups by fitting an interaction term (p value for significance <0.05). RESULTS: At study initiation, 5095 (50%) CANVAS Program participants were treated with insulin, 2100 (21%) had an HbA1c > 74.9 mmol/mol (9.0%) and the median duration of diabetes was 12.6 years (interquartile interval 8.0-18 years). Canagliflozin reduced MACE (HR 0.86 [95% CI 0.75, 0.97]) with no evidence that the benefit differed between subgroups defined by the number of glucose-lowering treatments, the duration of diabetes or baseline HbA1c (all p-heterogeneity >0.17). Canagliflozin reduced MACE in participants receiving insulin with no evidence that the benefit differed from other participants in the trial (HR 0.85 [95% CI 0.72, 1.00]). Similar results were observed for other cardiovascular outcomes and for the combined kidney outcome (HR for combined kidney outcome 0.60 [95% CI 0.47, 0.77]), with all p-heterogeneity >0.37. CONCLUSIONS/INTERPRETATION: In people with type 2 diabetes mellitus at high cardiovascular risk, there was no evidence that cardiovascular and renal protection with canagliflozin differed across subgroups defined by baseline treatment intensity, duration of diabetes or HbA1c.

来源:Diabetologia,查看原文。版权归原作者所有。

引用

  1. Young TK, Li JW, Kang A, et al. Effects of canagliflozin compared with placebo on major adverse cardiovascular and kidney events in patient groups with different baseline levels of HbA1c, disease duration and treatment intensity: results from the CANVAS Program. Diabetologia. 2021. PMID: 34448033. doi:10.1007/s00125-021-05524-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。